Bill.com, Sunrun, First Solar, JM Smucker, Summit Therapeutics: Trending by Analysts

Analysts are intrested in these 5 stocks: ( (BILL) ), ( (RUN) ), ( (FSLR) ), ( (SJM) ) and ( (SMMT) ). Here is a breakdown of their recent ratings and the rationale behind them.

Bill.com Holdings has seen a shift in analyst sentiment, with Chris Quintero from Morgan Stanley downgrading the stock to Hold. The previous optimism surrounding Bill.com’s potential for growth and monetization has been tempered by recent macroeconomic volatility affecting small and medium-sized businesses (SMBs). Despite the downgrade, there is still a long-term positive outlook for Bill.com, with a belief in its ability to expand and monetize its platform. The price target has been adjusted to $55, reflecting the current uncertainties but also acknowledging the limited downside due to its valuation.

Sunrun faces a challenging environment as analyst Julien Dumoulin Smith from Jefferies downgrades the stock to Sell. The residential solar market is under pressure due to potential changes in tax incentives and macroeconomic uncertainties. Despite Sunrun’s ability to adapt, the broader market conditions and legislative changes pose significant headwinds. The price target has been set at $5, with concerns about the company’s ability to navigate these challenges in a contracting market.

First Solar, on the other hand, has received a boost with an upgrade to Buy from analyst Julien Dumoulin Smith at Jefferies. The company is well-positioned to benefit from the current market dynamics, particularly with its US-made products gaining an advantage due to import restrictions. The price target has been raised to $192, reflecting the company’s potential to capitalize on favorable pricing and its strategic positioning in the utility-scale solar market.

JM Smucker has been upgraded to Buy by analyst Robert Dickerson from Jefferies, despite recent challenges. The company’s stock pullback is seen as an overreaction to lowered expectations from Hostess. Smucker’s portfolio is considered growth-advantaged compared to peers, and the current valuation is seen as undervalued. The price target is set at $115, with the belief that the company’s growth potential is not fully appreciated by the market.

Summit Therapeutics has been initiated with a Sell rating by analyst Daina Graybosch from Leerink Partners. While the company’s bispecific drug Ivonescimab shows promise, there are concerns about its ability to capture a significant share of the market due to intense competition. The price target is set at $12, with expectations of modest benefits from the drug and the need for strategic partnerships to enhance its portfolio.